MiR-9-5p Inhibits the MMP-Induced Neuron Apoptosis Through Regulating SCRIB/-Catenin Signaling in Parkinson's Disease

Overview

Journal Oxid Med Cell Longev

Publisher Wiley

Specialties Cell Biology
Endocrinology

Date 2022 May 5

PMID 35509839

Authors

Zhenyong Xiao

Zhenxing Yan

Xiang Sun

Zhiyuan Zhu

Baoyan Wang

Mengqi Gao

Fengfei Lu

Jian Liu

Zhitao Zong

Hongbo Zhang

Yanwu Guo

Affiliations

Soon will be listed here.

Abstract

The pathogenesis of Parkinson's disease remains unclear that there is no cure for Parkinson's disease yet. The abnormal expressions of certain miRNA are closely related to the occurrence and progression of Parkinson's disease. Here, we demonstrate that miR-9-5p inhibits the dopaminergic neuron apoptosis via the regulation of -catenin signaling which directly targets SCRIB, a tumor suppressor gene. Besides, miR-9-5p improved the motor function of mice with Parkinson's disease. The results of this study suggest that miR-9-5p might be a potential therapeutic target against Parkinson's disease.

Citing Articles

Increased expression of plasma mir-9-3p and let-7b-3p in methamphetamine use disorder and its clinical significance.

Wang W, Li C, Sun G, Qiu C, Fan J, Jin Y Sci Rep. 2024; 14(1):31729.

PMID: 39738153 PMC: 11686234. DOI: 10.1038/s41598-024-81921-x.

Recent Advances in the miRNA-Mediated Regulation of Neuronal Differentiation and Death.

Patranabis S Neuromolecular Med. 2024; 26(1):52.

PMID: 39648193 DOI: 10.1007/s12017-024-08820-2.

References

Alieva A, Filatova E, Karabanov A, Illarioshkin S, Limborska S, Shadrina M . miRNA expression is highly sensitive to a drug therapy in Parkinson's disease. Parkinsonism Relat Disord. 2014; 21(1):72-4. DOI: 10.1016/j.parkreldis.2014.10.018. View

LEpiscopo F, Tirolo C, Testa N, Caniglia S, Morale M, Cossetti C . Reactive astrocytes and Wnt/β-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neurobiol Dis. 2010; 41(2):508-27. PMC: 3558878. DOI: 10.1016/j.nbd.2010.10.023. View

Tolosa E, Botta-Orfila T, Morato X, Calatayud C, Ferrer-Lorente R, Marti M . MicroRNA alterations in iPSC-derived dopaminergic neurons from Parkinson disease patients. Neurobiol Aging. 2018; 69:283-291. DOI: 10.1016/j.neurobiolaging.2018.05.032. View

Poewe W, Seppi K, Tanner C, Halliday G, Brundin P, Volkmann J . Parkinson disease. Nat Rev Dis Primers. 2017; 3:17013. DOI: 10.1038/nrdp.2017.13. View

Angelopoulou E, Paudel Y, Piperi C . miR-124 and Parkinson's disease: A biomarker with therapeutic potential. Pharmacol Res. 2019; 150:104515. DOI: 10.1016/j.phrs.2019.104515. View

Ghavami S, Shojaei S, Yeganeh B, Ande S, Jangamreddy J, Mehrpour M . Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog Neurobiol. 2013; 112:24-49. DOI: 10.1016/j.pneurobio.2013.10.004. View

Nguyen M, Wong Y, Ysselstein D, Severino A, Krainc D . Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson's Disease. Trends Neurosci. 2018; 42(2):140-149. PMC: 6452863. DOI: 10.1016/j.tins.2018.11.001. View

Fricker M, Tolkovsky A, Borutaite V, Coleman M, Brown G . Neuronal Cell Death. Physiol Rev. 2018; 98(2):813-880. PMC: 5966715. DOI: 10.1152/physrev.00011.2017. View

Saraiva C, Paiva J, Santos T, Ferreira L, Bernardino L . MicroRNA-124 loaded nanoparticles enhance brain repair in Parkinson's disease. J Control Release. 2016; 235:291-305. DOI: 10.1016/j.jconrel.2016.06.005. View

10.

Tansey M, Romero-Ramos M . Immune system responses in Parkinson's disease: Early and dynamic. Eur J Neurosci. 2018; 49(3):364-383. PMC: 6391192. DOI: 10.1111/ejn.14290. View

11.

Che H, Sun L, Guo F, Niu H, Su X, Bao Y . Expression of amyloid-associated miRNAs in both the forebrain cortex and hippocampus of middle-aged rat. Cell Physiol Biochem. 2014; 33(1):11-22. DOI: 10.1159/000356646. View

12.

Nakamori M, Junn E, Mochizuki H, Mouradian M . Nucleic Acid-Based Therapeutics for Parkinson's Disease. Neurotherapeutics. 2019; 16(2):287-298. PMC: 6554378. DOI: 10.1007/s13311-019-00714-7. View

13.

Juzwik C, Drake S, Zhang Y, Paradis-Isler N, Sylvester A, Amar-Zifkin A . microRNA dysregulation in neurodegenerative diseases: A systematic review. Prog Neurobiol. 2019; 182:101664. DOI: 10.1016/j.pneurobio.2019.101664. View

14.

Sethi P, Lukiw W . Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer's disease temporal lobe neocortex. Neurosci Lett. 2009; 459(2):100-4. DOI: 10.1016/j.neulet.2009.04.052. View

15.

Marchetti B, Tirolo C, LEpiscopo F, Caniglia S, Testa N, Smith J . Parkinson's disease, aging and adult neurogenesis: Wnt/β-catenin signalling as the key to unlock the mystery of endogenous brain repair. Aging Cell. 2020; 19(3):e13101. PMC: 7059166. DOI: 10.1111/acel.13101. View

16.

Schulz J, Takousis P, Wohlers I, Itua I, Dobricic V, Rucker G . Meta-analyses identify differentially expressed micrornas in Parkinson's disease. Ann Neurol. 2019; 85(6):835-851. DOI: 10.1002/ana.25490. View

17.

LEpiscopo F, Tirolo C, Testa N, Caniglia S, Morale M, Deleidi M . Plasticity of subventricular zone neuroprogenitors in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease involves cross talk between inflammatory and Wnt/β-catenin signaling pathways: functional consequences for.... J Neurosci. 2012; 32(6):2062-85. PMC: 3556384. DOI: 10.1523/JNEUROSCI.5259-11.2012. View

18.

Daulat A, Silveira Wagner M, Walton A, Baudelet E, Audebert S, Camoin L . The Tumor Suppressor SCRIB is a Negative Modulator of the Wnt/β-Catenin Signaling Pathway. Proteomics. 2019; 19(21-22):e1800487. DOI: 10.1002/pmic.201800487. View

19.

Schapira A . Etiology and pathogenesis of Parkinson disease. Neurol Clin. 2009; 27(3):583-603, v. DOI: 10.1016/j.ncl.2009.04.004. View

20.

Leggio L, Vivarelli S, LEpiscopo F, Tirolo C, Caniglia S, Testa N . microRNAs in Parkinson's Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches. Int J Mol Sci. 2017; 18(12). PMC: 5751299. DOI: 10.3390/ijms18122698. View